Guggenheim Cuts GeneDx (NASDAQ:WGS) Price Target to $70.00

GeneDx (NASDAQ:WGS) had its target price dropped by Guggenheim from $100.00 to $70.00 in a report issued on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the stock. Guggenheim’s price target suggests a potential upside of 3.05% from the stock’s previous close.

WGS has been the topic of a number of other reports. Weiss Ratings reaffirmed a “sell (d)” rating on shares of GeneDx in a research note on Wednesday, January 21st. Jefferies Financial Group set a $150.00 target price on shares of GeneDx in a research note on Monday, February 23rd. Wall Street Zen downgraded GeneDx from a “buy” rating to a “hold” rating in a research report on Sunday, February 8th. Wells Fargo & Company restated an “overweight” rating and issued a $75.00 target price on shares of GeneDx in a research report on Tuesday. Finally, Canaccord Genuity Group set a $100.00 target price on GeneDx and gave the company a “buy” rating in a research report on Monday, April 20th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $98.33.

GeneDx Stock Performance

WGS opened at $67.93 on Tuesday. The firm has a market capitalization of $1.99 billion, a PE ratio of -90.57 and a beta of 2.06. GeneDx has a twelve month low of $55.17 and a twelve month high of $170.87. The firm’s 50-day moving average price is $71.45 and its 200 day moving average price is $107.17. The company has a current ratio of 2.46, a quick ratio of 2.34 and a debt-to-equity ratio of 0.16.

GeneDx (NASDAQ:WGS) last posted its quarterly earnings results on Monday, May 4th. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.22). The business had revenue of $102.25 million for the quarter, compared to analyst estimates of $112.46 million. GeneDx had a positive return on equity of 14.73% and a negative net margin of 4.92%.During the same quarter in the previous year, the firm posted ($0.23) earnings per share. As a group, sell-side analysts expect that GeneDx will post 0.75 EPS for the current fiscal year.

Insider Activity at GeneDx

In related news, CFO Kevin Feeley sold 392 shares of the company’s stock in a transaction that occurred on Wednesday, April 29th. The shares were sold at an average price of $65.19, for a total transaction of $25,554.48. Following the sale, the chief financial officer directly owned 34,942 shares of the company’s stock, valued at $2,277,868.98. This represents a 1.11% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Keith A. Meister bought 140,026 shares of the business’s stock in a transaction that occurred on Thursday, March 5th. The shares were acquired at an average cost of $81.19 per share, for a total transaction of $11,368,710.94. Following the completion of the purchase, the director owned 3,228,150 shares in the company, valued at $262,093,498.50. This trade represents a 4.53% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders sold a total of 109,989 shares of company stock valued at $7,888,023 over the last 90 days. Insiders own 29.60% of the company’s stock.

Institutional Investors Weigh In On GeneDx

Large investors have recently added to or reduced their stakes in the business. Jones Financial Companies Lllp increased its stake in GeneDx by 664.3% during the 3rd quarter. Jones Financial Companies Lllp now owns 214 shares of the company’s stock worth $25,000 after buying an additional 186 shares during the period. Kestra Advisory Services LLC purchased a new stake in GeneDx during the 4th quarter worth approximately $27,000. Fifth Third Bancorp purchased a new stake in GeneDx during the 1st quarter worth approximately $31,000. Quarry LP increased its stake in GeneDx by 248.8% during the 3rd quarter. Quarry LP now owns 293 shares of the company’s stock worth $32,000 after buying an additional 209 shares during the period. Finally, Ramirez Asset Management Inc. acquired a new position in GeneDx during the 4th quarter worth approximately $33,000. 61.72% of the stock is owned by hedge funds and other institutional investors.

Key GeneDx News

Here are the key news stories impacting GeneDx this week:

• Positive Sentiment: Strong underlying volume growth: management reported 34% year‑over‑year volume growth in exome and genome testing, supporting longer‑term demand for the core business. GeneDx Reports First Quarter 2026 Financial Results and Updates Full-Year Outlook
• Neutral Sentiment: Revenue and gross profit were higher year‑over‑year ($102.3M revenue; gross profit up ≈17%), indicating growth despite near‑term margin pressure. GeneDx Holdings Corp. (WGS) Stock Falls on Q1 2026 Earnings
• Neutral Sentiment: Conference call materials and transcript are available for more detail on drivers and cadence of margin recovery; listeners can assess management commentary for guidance color. GeneDx Holdings Corp. (WGS) Q1 2026 Earnings Call Transcript
• Negative Sentiment: Q1 EPS missed materially: GAAP loss per share of ($0.28) vs. consensus loss of ($0.06), with revenue below estimates (~$102.25M vs. ~$112–114M est.), a primary catalyst for downward pressure. GeneDx Holdings Corp. (WGS) Reports Q1 Loss, Lags Revenue Estimates
• Negative Sentiment: Full‑year revenue guidance markedly below consensus: management set FY revenue of roughly $475–$490M vs. street ~$549M, increasing downside risk to near‑term estimates and valuation. GeneDx Reports First Quarter 2026 Financial Results and Updates Full-Year Outlook
• Negative Sentiment: Profitability and cash flow stress: the quarter showed a large operating and net loss and meaningful operating cash outflow, which raises execution and financing concerns until margins and cash generation improve. GeneDx Holdings Corp. (WGS) Stock Falls on Q1 2026 Earnings
• Negative Sentiment: Insider selling: recent disclosure shows the CFO sold shares (~$25.6k reported) and several insiders have sold shares in recent months, which markets often view as a negative signal. Insider Selling: GeneDx (NASDAQ:WGS) CFO Sells $25,554.48 in Stock

GeneDx Company Profile

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.